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Abstract
Background: Recent clinical and animal studies have shown that extracorporeal shock wave therapy has a promoting
influence on the healing process of musculoskeletal disorders. However, the underlying biological effects of extracorporeal
shock wave therapy on human skeletal muscle cells have not yet been investigated.
Methods: In this study, we investigated human skeletal muscle cells after exposure to radial extracorporeal shock waves
in a standardized in vitro setup. Cells were isolated from muscle specimens taken from adult patients undergoing spine
surgery. Primary muscle cells were exposed once or twice to radial extracorporeal shock waves in vitro with different
energy flux densities. Cell viability and gene expression of the paired box protein 7 (Pax7), neural cell adhesion molecule
(NCAM), and myogenic factor 5 (Myf5) and MyoD as muscle cell markers were compared to non-treated muscle cells that
served as controls.
Results: Isolated muscle cells were positive for the hallmark protein of satellite cells, Pax7, as well as for the muscle cell
markers NCAM, MyoD, and Myf5. Exposure to radial extracorporeal shock waves at low energy flux densities enhanced
cell viability, whereas higher energy flux densities had no further significant impact. Gene expression analyses of muscle
specific genes (Pax7, NCAM, Myf5, and MyoD) demonstrated a significant increase after single exposure to the highest
EFD (4 bar, 0.19 mJ/mm2) and after double exposure with the medium EFDs (2 and 3 bar; 0.09 and 0.14 mJ/mm2,
respectively). Double exposure of the highest EFD, however, results in a significant down-regulation when compared
to single exposure with this EFD.
Conclusions: This is the first study demonstrating that radial extracorporal shock wave therapy has the potential to
modulate the biological function of human skeletal muscle cells. Based on our experimental findings, we hypothesize
that radial extracorporal shock wave therapy could be a promising therapeutic modality to improve the healing process
of sports-related structural muscle injuries.
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Background
Muscle injuries are very common in athletes. They repre-
sent more than 30% of all injuries in professional soccer
and cause about one quarter of total injury absence [1].
Despite the growth of knowledge in therapy in professional
sports, the treatment options of structural muscle injuries
are still very limited. Furthermore, there is no consensus
on their management so far. Recently, several injection
methods were reported to shorten the recovery time after
muscle strain injuries [2]. The injection of local anesthetics,
Actovegin and Traumeel, as well as platelet-rich plasma
(PRP) were most frequently reported but the results
concerning these therapies are ambivalent [3–5]. Despite
the fact that there are few clinical studies illustrating suc-
cessful therapy, only limited scientific evidence is available
supporting the general use of these agents.
Extracorporeal shock wave therapy (ESWT) may serve
as a non-invasive therapeutic option for muscle injuries.
Two types of extracorporeal shock waves (ESWs) are used
in medical therapy: focused extracorporeal shock waves
(fESWs) and radial extracorporeal shock waves (rESWs)
[6]. Both are single acoustic impulses with an initial high
positive peak pressure between 10 and 100 megapascals
(MPa) reached in less than 1 μs [7]. The positive pressure
amplitude is followed by a low tensile amplitude of a few
microseconds duration that can generate cavitation [8, 9].
They are further characterized by a short life cycle of
approximately 10–20 μs and a broad frequency spectrum
[10]. Focused ESWs differ from rESWs in the penetration
depth into the tissue, some physical characteristics, and
the technique for generating them [6, 9].
For more than a decade, ESWT has been successfully
used in the treatment of sports-related over-use tendino-
pathies such as proximal plantar fasciopathy, Achilles
tendinopathy, proximal hamstring tendinopathy, lateral
epicondylitis of the elbow, and calcifying or non-calcific
tendinitis of the shoulder [6, 11–15]. Besides this, ESWT
can reduce pain and muscle tone in multiple sclerosis
(MS) patients without adverse effects, and is a therapeutic
option for treating pain and muscle hypertonia in patients
with cerebral palsy and stroke [16]. It is effective for the
purpose of pain relief and improving cervical range of
motion in patients with myofascial pain syndrome [17].
Furthermore, ESWT can improve microcirculation blood
flow of ischemic limbs in patients with peripheral arterial
disease [18]. The primary advantage of ESWT is its
non-invasive nature and very low rate of complications
when applied to musculoskeletal tissues.
Human skeletal muscle tissue possesses a remarkable
capacity to regenerate in response to muscle injury. Adult
myofibers are terminally differentiated so that muscle
repair is largely attributed to a distinct population of
resident myogenic progenitor cells termed satellite cells
[19]. This cell population is a pool of stem cells that reside
between the sarcolemma and the basal lamina surrounding
each myofiber in a quiescent state [20]. Upon muscle
injury, satellite cells become activated, proliferate, and
fuse either with existing fibers or with themselves to
form new myofibers [19]. In immature skeletal muscle
satellite cells, distinct patterns of myogenic proteins are
expressed [20]. Quiescent satellite cells express the paired-
box transcription factor paired box protein 7 (Pax7) [21]
and when activated, they co-express Pax7 with myogenic
differentiation (MyoD) [22], a key transcription factor for
myogenic differentiation and a member of the myogenic
regulatory factor (MRF) family, comprising MyoD,
myogenic factor 5 (Myf5), Myogenin, and MRF-4 [23].
Pax7 is specifically required for maintenance of postnatal
muscle. The lack of satellite cells in Pax7 knock-out mice
suggests that this factor is critical for their biogenesis [24].
Most satellite cells proliferate, down-regulate Pax7, and
differentiate. By contrast, others maintain Pax7 but lose
MyoD and return to a state resembling quiescence [25].
Myf5 is a direct target gene of Pax7 and transcription
of Myf5 directly varies with Pax7 levels [26]. Neural cell
adhesion molecule (NCAM) is expressed in proliferating
myoblasts among cells cultured from skeletal muscle [27].
Most insights into this complex network of muscle
regeneration resulted from research on murine in vitro
and in vivo models.
So far, little is known about the biological and molecular
effects of ESWT on regenerative muscle cells. Based on
the above-mentioned positive clinical and experimental
findings, we hypothesize that radial extracorporeal shock
wave therapy (rESWT) could be a promising therapeutic
modality to improve the healing process of sports-related
structural muscle injuries by regulating satellite cells. In
the present study, for the first time, biological effects of
rESWT on human primary skeletal muscle cells under
controlled in vitro conditions are described.
Methods
Cell cultures
Human skeletal muscle cells were isolated from muscle
specimens taken from four patients (all male, aged 27,
46, 55, and 67 years) undergoing spinal surgery for lumbar
disc disease in two cases or fracture of the thoracic spine
at our Department. Muscle tissue used in the present
study was considered to be surgical waste and would
otherwise have been discarded by the hospital. The
patients included were neither operated before nor
suffered from muscle diseases or any other condition
known to affect muscle healing. All experiments were
approved by the Ethics Committee of Landesärztekammer
Rheinland—Pfalz by an arrangement concerning excess
material. Written informed consent was obtained from
every participating patient.
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Muscle tissue was processed directly after excision.
Cell isolation was performed according to an established
protocol [27]. Fibrous tissue and perimysium were carefully
removed under sterile conditions. The muscle tissue was cut
into small pieces (1 mm2) and rinsed in phosphate-buffered
saline (PBS, Dulbecco’s phosphate buffered saline, Gibco/
Life Technologies, Paisley, UK) to remove blood and fat resi-
dues. After digestion with type II collagenase (Worthington
Biochemical Corp., Lakewood, NJ, USA), muscle solution
was treated with 0.25% trypsine/1 mM EDTA (Biochrom,
Berlin, Germany) in a water bath at 37 °C. The specimens
were filtered through a cell strainer (100 μm mesh; BD
Biosciences, Heidelberg, Germany) to obtain a single-cell
suspension and finally centrifuged at 1.4 × 103 rpm. The
pellet was re-suspended in medium (Skeletal Muscle Cell
Growth Medium; PromoCell) supplemented with antibiotics
(10,000 U/ml penicillin G sodium and 10,000 μg/ml
streptomycin sulfate; Gibco/Life Technologies) and cells
were seeded in collagen-coated (10% type I collagen;
Discovery Labware, Woburn, MA, USA) culture flasks
and incubated in a humidified atmosphere of 5% CO2 at
37 °C. Culture media were changed every second day, and
preconfluent muscle cells were passaged using accutase
(PAA Laboratories, Cölbe, Germany). For cell quantifica-
tion, we used a Luna™ Cell Counting Slide and the Cell
Counter Cellometer® Auto T4 (Nexcelom Bioscience LLC,
Lawrence, MA 01843, USA). Early passage cells (passages
2–4) were used for all experiments. Cell differentiation
was performed using the Skeletal Muscle Differentiation
Medium (PromoCell, Heidelberg, Germany) by changing
medium after cells reached 70–80% confluence for 5 days
in culture. Due to limited material, not all experiments
could be performed with cells isolated from all patients.
Immunofluorescence staining
The phenotype of the cultured cells was determined by
immunofluorescence staining. Cells were seeded on
chamber slides (Chamber Slides System LAB-TEK, Nalgene
Nunc International, Rochester, NY, USA) coated with
collagen (10% type I collagen; Discovery Labware). Cells
were fixed with − 20 °C methanol (AppliChem, Darmstadt,
Germany) followed by washing in − 20 °C aceton (Sigma-
Aldrich, St. Louis, MO, USA). After 20-min incubation in
PBS, cells were incubated with primary antibodies against
Pax7 (dilution 1:200, mouse monoclonal anti-PAX7 anti-
body, ab92317; Abcam, Cambridge, UK), NCAM (dilution
1:200, mouse monoclonal Anti-NCAM (ERIC-1), ab6123;
Abcam), and Myf-5 (dilution 1:100, M-18 sc-31,949, Santa
Cruz Biotechnology, Dallas, USA) in 0.5% BSA/PBS (PAA
Laboratories, Pasching, Austria) overnight at 4 °C. Then
cells were incubated with secondary antibodies anti-mouse
Alexa Fluor™ 488 (dilution 1:200, A-11001, Invitrogen/Life
Technologies, Carlsbad, CA, USA) and anti-goat Cy3
(dilution 1:450, 705-165-003, Dianova, Hamburg, Germany)
in PBS containing 0.5% BSA for 2 h at room temperature in
the dark and washed twice with PBS. Nuclei were stained
with mounting medium containing DAPI (1.5 μg/ml,
Vectashield, Vector Laboratories, Burlingame, CA, USA).
Myosin antibody was used to detect myotube formation
of differentiated skeletal muscle cells in our isolated
cultures (dilution 1:200, mouse monoclonal Anti-Fast
Myosin Skeletal Heavy chain antibody (MY-32), ab51263,
Abcam). Secondary antibody (anti-mouse Alexa Fluor™
488, A-11001, Invitrogen/Life Technologies) was used as
described above.
Microscopy
Microscopy was performed with an EVOS Digital
Inverted Microscope (Life Technologies) and × 4 (Figs. 2a
and 3j–l), × 10 (Fig. 2b), and × 40 (Fig. 3a–i) objectives.
Both phase contrast and fluorescence modes were used.
The final figures were assembled using Corel Photo-Paint
X6 and Corel Draw X6 (both versions 16.1.0.843; Corel,
Ottawa, Canada).
Exposure of cells to radial extracorporeal shock waves in
vitro
Exposure to radial extracorporeal shock waves (rESWs)
in vitro was performed with a Swiss DolorClast device
(Electro Medical Systems, Nyon, Switzerland) and its
“Radial” handpiece (Fig. 1a). The rational for changing
the pressure as well as the energy flux density directly
reflected the working mechanism of the pneumatic radial
extracorporeal shock wave device that was used in the
present study (Swiss DolorClast, Electro Medical Systems,
Nyon, Switzerland) and published by Császár et al. [8].
Both the 6-mm and the 10-mm applicators were used.
Further, 8 × 104 human muscle cells per well were
seeded in 6-well plates and incubated for 2 days. Then
10 ml growth medium were added to each well, the “Radial”
handpiece of the rESWT device was placed in a fixed pos-
ition using a customized holder (Fig. 1a) and the applicator
of the handpiece immerged into the solution with a
distance of 13 mm to the bottom of the wells (Fig. 1b). The
optimum number of cells per well and a suitable distance
of the applicator to the bottom of the wells were deter-
mined in pre-tests (data not shown). Parameters were
chosen according to the rate of viable cells after exposure
to rESWs.
In the main experiments, rESWs were applied at a
frequency of 10 per second (i.e., at 10 Hz) and 500 impulses.
Different treatment of various groups is described in
Table 1.
Cells in groups A1 to A4 were exposed to rESWs on
day 1 and were analyzed on day 3 (i.e., single exposure
to rESWs), whereas cells in groups B1 to B4 were exposed
to rESWs on days 1 and 5 and were analyzed on day 7.
Energy flux density (EFD) data at a distance of 13 mm to
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the applicator were provided by Electro Medical Systems
and were as follows: groups A1 and B1: 0.0006 mJ/mm2
(6-mm applicator; device operated at 1 bar air pressure;
5% of the EFD applied to groups A4 and B4); groups
A2 and B2: 0.0012 mJ/mm2 (6-mm applicator; device
operated at 2 bar air pressure; 10% of the EFD applied
to groups A4 and B4); groups A3 and B3: 0.009 mJ/mm2
(10-mm applicator; device operated at 3 bar air pressure;
75% of the EFD applied to groups A4 and B4); and groups
A4 and B4: 0.012 mJ/mm2 (10-mm applicator; device
operated at 4 bar air pressure).
Cell viability assay
Optimal number of cells was determined in pre-tests.
Viability assays were performed either on day 3 (single
exposure to rESWs on day 1, groups A1 to A4) or day 7
(double exposure to rESWs on days 1 and 5, groups B1 to
B4), respectively, using the alamarBlue® assay (Invitrogen/
Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions. For every measurement,
alamarBlue® solution was added to each well and incubated
for 4 h. Samples were examined in triplicates, and the
emission was measured at a wavelength of 580–640 nm
using the GloMax® Multidetection System (Promega,
Madison, WI, USA).
This experiment was performed with cells isolated from
three patients and each cell type was used in triplicates.
As we used a non-treated control as control for each treat-
ment group, n for both control groups (A0 and B0) n = 36
and for all treated groups (A1–4 and B1–4) n = 9.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from cells on day 3 (groups
A0 to A4) or day 7 (groups B0 to B4). The purification
was performed using the RNeasy Mini Kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instruc-
tions. RNA quality and concentration were measured photo-
metrically. The A 260/280 ratio of samples was between 1.9
and 2.1. To avoid any contamination with DNA, DNase
(QIAGEN) was used. Reverse transcription was performed
using 2 μg RNA, Superscript-Reverse transcriptase III
(Invitrogen/Life Technologies) Random Primers (Promega,
Fig. 1 Exposure of human skeletal muscle cells to radial extracorporeal shock waves in vitro. a Positioning of the handpiece of a radial
extracorporeal shock wave (rESW) device (Swiss DolorClast; Electro Medical Systems, Nyon, Switzerland) in a fixed position using a customized
holder. b Exposure of cells cultivated at the bottom of 6-well plates to rESWs at a constant distance of 13 mm. The arrows point to the applicator
of the handpiece that is emitting the rESWs
Table 1 Exposure of human skeletal muscle cells to radial extracorporeal shock waves (rESWs) in vitro
Group Applicator [∅] AP [bar/energy] Energy flux density [%] ESW-application on day 1 ESW-application on day 5
A0 – – – – –
A1 6 mm 1/0.05 mJ/mm2 5 + –
A2 6 mm 2/0.09 mJ/mm2 10 + –
A3 10 mm 3/0.14 mJ/mm2 75 + –
A4 10 mm 4/0.19 mJ/mm2 100 + –
B0 – – – –
B1 6 mm 1/0.05 mJ/mm2 5 + +
B2 6 mm 2/0.09 mJ/mm2 10 + +
B3 10 mm 3/0.14 mJ/mm2 75 + +
B4 10 mm 4/0.19 mJ/mm2 100 + +
AP, air pressure at which the rESW was operated; energy flux density of the rESWs applied on days 1 and day 5, groups A1–A4 were treated once, whereas groups
B1–B4 were treated twice. A0 and B0 were used as untreated controls
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Madison, WI, USA), and dNTPs (Bioron GmbH,
Ludwigshafen, Germany).
Gene expression analyses for Pax7, NCAM, Myf5, and
MyoD were performed by quantitative RT-PCR with
QuantiTect Primer Assays (Table 2) (QIAGEN), the
Power SYBR Green PCR Master Mix, and cDNA using
the 7300 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA).
All samples were examined in triplicates. Following
steps were used for amplification: initial denaturation at
95 °C for 10 min, followed by 40 cycles of DNA amplifi-
cation (denaturing for 15 s at 95 °C, annealing for 30 s
at 55 °C, and elongation for 35 s at 72 °C) followed by
dissociation curve. Gene expression was normalized
using 18S. The comparative threshold cycle (Ct) method
was used to calculate the expression and presented as
2-ΔΔCt values, respectively.
This experiment was performed with cells isolated from
four patients and each cell type was used in triplicates. As
we used a non-treated control as control for each treat-
ment group, n for both control groups (A0 and B0) n = 36.
Due to limited material, cells from two patients were used
for the treated groups (A1–4 and B1–4) resulting in n = 6.
Statistical analysis
Mean and standard deviation were calculated for all
variables of the cell viability assay. Effects of rESWs
were tested using the F test followed by comparison of
individual groups to the corresponding control group
using Dunnett’s test. Furthermore, median were calculated
for effects of rESWs on gene expression. Kruskal-Wallis
test followed by comparison of individual groups to the
corresponding control group and to each other group
using the Mann-Whitney U test were used. For all
analyses, a p value < 0.05 was considered statistically
significant. Calculations were performed using SPSS
(Version 23 for Windows; IBM, Armonk, NY, USA).
Results
Confirmation of the presence of muscle cells in primary
culture
Only a few days after seeding, cultured human skeletal
muscle cells demonstrate the typical structure and
formation of stellate cells (Fig. 2a). After 5 days in differ-
entiation medium, cells were differentiated and started
to form myotubes (Fig. 2b).
Human skeletal muscle cell cultures were positive for
Pax7 (Fig. 3a–c), NCAM (Fig. 3d–f ), and Myf5 (Fig. 3g–i)
demonstrated by immunofluorescence staining indicating
the presence of a mixed muscle cell culture. Myosin
staining (Fig. 3j–l) evidenced the presence of myotube
formation of mature muscle cells. The percentage of Pax7
positive cells hallmarking satellite cells was comparatively
low as expected.
Viability of human skeletal muscle cells was influenced by
exposure to radial extracorporeal shock waves in vitro in
a dose-dependent manner
Both single exposure as well as double exposure of human
primary skeletal muscle cells to rESWs in vitro influenced
viability of the cells. Medium strength of shock wave
application (2 and 3 bar; 0.09 and 0.14 mJ/mm2)
demonstrated the highest viability of muscle cells. Higher
shock wave application resulted in low viability of the
cells (Fig. 4). Although a tendency is clearly visible, the
differences are not statistically significant.
Exposure of human skeletal muscle cells to radial
extracorporeal shock waves in vitro had a dose-dependent
impact on gene expression
Our results demonstrate a dose-dependent effect of rESW
on gene expression of muscle-specific genes (Fig. 5). After
single exposure, Pax7 is significantly up-regulated in the
group with the highest air pressure (AP) and highest flux
density (FD, A4) compared to the non-treated control.
Interestingly, in the group with lower AP and FD, gene
expression is down-regulated. After double exposure
medium, AP and FD (B2 and B3) demonstrate the highest
effect on primary muscle cells. When comparing single
with double exposure, we see a significant up-regulation
of Pax7 gene expression in the groups A3 and B3
(3 bar, 0.14 mJ/mm2) and a significant down-regulation
between the groups A4 and B4 (4 bar, 0.19 mJ/mm2).
MyoD demonstrates a gene expression pattern comparable
to Pax7. Concerning gene expression of NCAM, our results
demonstrate a significant up-regulation compared to the
non-treated control group after single and double exposure
in the groups A3 and B3 (3 bar, 0.14 mJ/mm2) and single
exposure in group A4 (4 bar, 0.19 mJ/mm2). Double
exposure with the highest EFD results in a significant
down-regulation when compared to single exposure. Myf5
is significantly up-regulated after single exposure with the
highest EFD (A4, 4 bar, 0.19 mJ/mm2) and after double
exposure with the three highest EFD (groups B2–B4).
However, whereas double exposure with the second highest
EDF (3 bar, 0.14 mJ/mm2) results in the top value of Myf5
gene expression, double exposure with the highest EFD
Table 2 Primers used for quantitative real-time PCR in the
present study (all primers from QIAGEN, Hilden, Germany)
Product name Catalogue no.
Hs_MYF5_1_SG QuantiTect Primer Assay QT00027825
Hs_NCAM1_1_SG QuantiTect Primer Assay QT00071211
Hs_PAX7_1_SG QuantiTect Primer Assay QT00018942
Hs_RRN18S_1_SG QuantiTect Primer Assay QT00199367
Hs_Myod1_1_SG QuantiTect Primer Assay QT00209713
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results in a significant down-regulation when compared to
single exposure and group B3.
Discussion
ESWT has become an established non-invasive procedure
for the treatment of various musculoskeletal disorders
over the last two decades [6]. Stimulating effects of ESWs
on osteoblasts and fibroblasts were reported, as well as
induction of neovascularization and increased expression
of bone morphogenic proteins (BMPs) [28–32]. Beside
the beneficial effect on tissue healing, ESWs have anti-
inflammatory and analgesic effects [33, 34]. Furthermore,
Fig. 2 Low-resolution phase contrast of primary cultured human skeletal muscle cells and mature myotubes. a, b Phase contrast imaging of
muscle cells; scale bar in (a) represents 1000 μm and 400 μm in (b)
Fig. 3 Immunofluorescence imaging of cultured human skeletal muscle cells. Immunofluorescence staining for Pax7 (a–c), NCAM (d–f), Myf5 (g–i),
and Myosin (j–l). The scale bars represent 100 μm for a–i and 1000 μm for j–l.
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Fig. 4 Results of alamarBlue® Assay to determine cell viability. The panels show Tukey boxplots of absolute values of the emission at 570 nm of
the alamarBlue® assay performed for cells in groups A0 to A4 (light gray bars) and groups B0 to B4 (dark gray bars) after exposure to radial
extracorporeal shock waves (groups A1–A4 and B1–B4) or sham-exposure (groups A0 and B0) as outlined in Table 1. Results of statistical analysis
are indicated (Dunnett’s test; comparison to control)
Fig. 5 Results of qRT-PCR analysis. The panels show Tukey boxplots of 2-ΔΔCt values of mRNA expression of Pax7, NCAM, Myf5, and MyoD
determined with quantitative real-time polymerase chain reaction on day 3 (groups A1 to A4; light gray bars, single exposure to rESW) or day 7
(groups B1 to B4; dark gray bars, double exposure to rESW) compared to the non-treated groups (A0 and B0, respectively). Statistical significances
between the groups on day 3 and day 7 as well as between day 3 and 7 are indicated with same letters. Statistical significance to the control
groups are indicated with asterisks (Mann-Whitney U test; comparison to control) with p < 0.05
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ESWT provides clinically favorable outcome to patients
with breast cancer-related lymphedema [35]. Although
there are some findings that indicate an acceleration of
tissue healing, the biological mechanisms of ESWTcausing
these noticed effects have remained largely unknown.
Skeletal muscle injuries are the most common reason
for missed playing time in athletes [1, 36]. The treatment
modalities of structural muscle injuries are still limited.
Recent clinical studies reported that ESWT can reduce
pain and muscle tone in multiple sclerosis (MS) patients
without adverse effects [37]. It is a therapeutic option in
rehabilitative medicine to treat pain and muscle hypertonia
in patients with cerebral palsy and stroke [16] and may
modulate the rheology of muscles [38] as well as neuro-
transmission at the neuromuscular junction [39].
The aim of the present study was to investigate bio-
logical effects of rESWs on human primary skeletal
muscle cells in vitro after single and double exposure with
different EFDs. Both single exposure as well as double
exposure influenced viability of the cells. Medium EFD
(2 and 3 bar; 0.09 and 0.14 mJ/mm2) demonstrated the
highest viability of muscle cells. Higher EFD resulted in
low viability of the cells (Fig. 4). Although a tendency is
clearly noticeable, the differences are not statistically
significant. Moreover, it could be speculated that double
exposure of shock waves with 4 bar and 0.19 mJ/mm2
which resulted in inhibition of cell viability could be due to
mechanical cell destruction of these high EFD. These
results are confirmed by gene expression analyses (see
below). Summarizing the effects of shock wave application
on muscle-specific gene expression, our results reveal that
a significant increase was observed for all tested genes after
single exposure to the highest EFD (4 bar, 0.19 mJ/mm2)
and after double exposure with the medium EFDs (2 and
3 bar; 0.09 and 0.14 mJ/mm2, respectively). Double
exposure of the highest EFD, however, results in a
significant down-regulation when compared to single
exposure with the same EFD. As this is in accordance
to the viability results, it should be considered for
therapeutical approaches; depending on the question
and injury, more frequent applications with lower EFDs
could be better than a single application with a higher
EFD. However, this has to be further analyzed in an in
vivo model of muscle injuries.
Myf5 is a direct target gene of Pax7 and transcription
of Myf5 directly varies with Pax7 levels. The fact that it
has been shown in the literature that Myf5 directly varies
with Pax7 does not necessarily mean that both genes need
to be up- or down-regulated at the same degree. The gene
expression of Pax7 in general is lower than of Myf5 as
Pax7 is a hallmark protein of quiescent satellite cells. As
we isolated cells from muscle biopsies, the percentage of
Pax7 positive cells hallmarking satellite cells was compara-
tively low as expected.
Human skeletal muscle cell cultures were positive for
Pax7 (Fig. 3a–c), NCAM (Fig. 3d–f ), and Myf5 (Fig. 3g–i)
demonstrated by immunofluorescence staining indicating
the presence of a mixed muscle cell culture at an early
time point of differentiation. Myosin staining (Fig. 3j–l)
evidenced the presence of myotube formation of mature
muscle cells. In our experiments, we worked with mixed
cultures and according to the expression of Myf5 with
cells at early stages of differentiation.
Previously, it has been reported that ESWT stimulates and
accelerates regenerative processes of acute muscle injuries in
adult Sprague-Dawley rats [40]. In this study, an acute
cardiotoxin-induced injury was set into the quadriceps
femoris muscle of rats in the experimental groups and ana-
lyzed by histomorphometry and immunohistochemistry.
Accordingly, rESWT might influence gene expression
and cell division of satellite cells in human skeletal
muscle in vivo. In general, these data support previous
findings that ESWT has an influence on biological cell
function. It is critical to note that in this mentioned
study [40], muscle injury of the quadriceps femoris
muscle was initiated using a cardiotoxin, causing irre-
versible depolarization until muscle fibers die. However,
this model may be of only limited relevance to muscle
injuries in sports medicine. It was recently found that in
models of muscle injury, the nature of the injury model
should be chosen carefully depending on the experimental
design and desired outcome [41]. This is due to the fact
that the trajectories of regenerative processes leading to
regeneration may considerably vary among models [41, 42].
Accordingly, it appears necessary to repeat the experiments
performed by Zissler et al. using a more relevant animal
model of sports-related muscle injury [43, 44]. Moreover,
Vetrano et al. reported promotion of cell growth of primary
human tenocytes after exposure to fESWs in vitro. Because
proliferation of tenocytes is considered to be crucial for
tissue repair, these results suggest that the clinical benefits
and the timing of ESWT may be explained by an increased
effectiveness of tissue healing mechanisms [45]. Further-
more, exposure of human tenocytes to ESWs in vitro
was able to induce cell proliferation and synthesis of
type I collagen, both appearing to be more pronounced
after 8 to 12 days following exposure [46]. Similar results
were recently reported for human fetal foreskin fibroblasts
after exposure to rESWs in vitro [47].
The EFD values of the rESWs reported in the present
study may appear very small compared to EFD values of
rESWs reported in clinical studies [6]. This is due to the
fact that the EFD values reported in the present study are
those measured at a distance of 13 mm to the applicator
of the rESW device in water, whereas in clinical studies on
rESWT, usually the EFD values obtained at the tip of the
applicator are reported. The latter is due to the fact that
unlike in the in vitro situation, the EFD of ESWs cannot
Mattyasovszky et al. Journal of Orthopaedic Surgery and Research  (2018) 13:75 Page 8 of 10
be reliably determined in vivo. However, preliminary data
indicated that for rESWs, measurements in muscle tissue
and water are consistent [48].
Finally, it should be pointed out that a certain limitation
of all studies revealing enhanced cell viability and gene
expression in connective tissue cells after exposure to
ESWs is its in vitro nature. Working with primary human
cells instead of cell lines has some disadvantages as
numerous factors could affect gene expression. Different
age of the donors is not the only factor in vivo that might
influence gene expression: gender, medications, traumatic
vs. degenerative disorders are just a few of them. The aim
of our study was to look for general regulating factors
under the influence of rESWs irrespective of age or
gender. Accordingly, the results of these studies cannot
directly be translated to the in vivo situation. On the other
hand, results of in vitro studies are very useful for stimu-
lating novel research in vivo. In this regard, the results of
the present study, which to our knowledge represent
the first biological effects of rESWs on human primary
skeletal muscle cells, may serve as a starting point for
future studies in vivo to evaluate the significance and
relevance of rESWT on the process of muscle healing.
Conclusion
In this in vitro study, we isolated and cultured primary
human skeletal muscle cells from biopsy specimens and
investigated the effect of radial extracorporal shock wave
therapy (rESWT) on human skeletal muscle cells. To the
best of our knowledge, this is the first study to provide
evidence that rESWT has the potential to modulate the
biological function of primary human muscle cells. rESWT
influences human skeletal muscle cell viability and regulates
the gene expression of muscle cell proteins in vitro, whereas
in our study, rESWT had a higher impact on cell differenti-
ation than on cell viability. rESWT could therefore offer
promising options in the therapy of sports-related structural
muscle injuries in Sports Medicine.
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